One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Accesshttps://doi.org/10.1093/annonc/mdz255.007
Copy DOI
Export
Save
Share
Cite Journal: Annals of Oncology |  Publication Date: Oct 1, 2019 |
 Citations: 5 |  License type: publisher-specific-oa |
Affiliation: Peter MacCallum Cancer Centre, Sir Charles Gairdner Hospital, Brigham and Women's Hospital, Moffitt Cancer Center, Royal Brisbane and Women's Hospital, Essen University Hospital, Memorial Sloan Kettering Cancer Center, Stanford University, University of Lübeck, University Hospital Schleswig-Holstein, Charité - Universitätsmedizin Berlin, Universitätsmedizin Göttingen, The University of Texas MD Anderson Cancer Center, New York University Langone Medical Center, Cleveland Clinic, Regeneron (United States), Royal North Shore Hospital
1318P - Phase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
